Biocytogen Pharmaceuticals-B(02315) plans to use idle funds for cash management.

Biocytogen Pharmaceuticals-B(02315) announced that in order to improve the efficiency of the company's use of its own funds, while ensuring that it does not affect the company's normal production and operation and ensuring the safety of the funds, the company plans to reasonably utilize some idle own funds for cash management. This can improve the efficiency of using its own funds, increase the company's cash assets returns, and obtain more investment returns for the company and shareholders. The company plans to use up to RMB 500 million (including the principal) of temporarily idle own funds for cash management, and within the aforementioned limit, the funds can be rolled over for use. The company plans to use temporarily idle own funds to purchase wealth management products issued by banks and other financial institutions with high security, good liquidity, and low risk for entrusted wealth management.